Aligos Therapeutics (ALGS) Expected to Announce Quarterly Earnings on Wednesday

Aligos Therapeutics (NASDAQ:ALGS) is anticipated to announce its Q2 2025 earnings results after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($2.35) per share and revenue of $0.43 million for the quarter.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($2.11) earnings per share for the quarter, topping the consensus estimate of ($2.80) by $0.69. Aligos Therapeutics had a positive return on equity of 14.67% and a negative net margin of 1,628.75%. The company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.33 million. On average, analysts expect Aligos Therapeutics to post $-10 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Aligos Therapeutics Price Performance

Shares of NASDAQ ALGS opened at $7.46 on Monday. The stock’s 50-day moving average is $7.64 and its two-hundred day moving average is $11.21. Aligos Therapeutics has a 1-year low of $3.76 and a 1-year high of $46.80. The company has a market cap of $45.58 million, a price-to-earnings ratio of -0.43 and a beta of 2.77.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aligos Therapeutics stock. Woodline Partners LP bought a new stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 315,383 shares of the company’s stock, valued at approximately $2,602,000. Woodline Partners LP owned 5.16% of Aligos Therapeutics as of its most recent SEC filing. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).